Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Innoviva Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
INVA
Nasdaq
2834
https://www.inva.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Innoviva Inc
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
- Mar 4th, 2024 9:01 pm
Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
- Feb 29th, 2024 9:37 pm
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
- Feb 29th, 2024 9:05 pm
Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition
- Feb 14th, 2024 7:44 am
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
- Jan 10th, 2024 11:16 pm
Innoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three years
- Dec 30th, 2023 1:34 pm
Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc
- Nov 18th, 2023 12:03 pm
Innoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
- Nov 14th, 2023 2:57 pm
Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million
- Nov 3rd, 2023 10:00 am
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Nov 1st, 2023 8:15 pm
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
- Nov 1st, 2023 8:05 pm
Calculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)
- Oct 18th, 2023 11:48 am
Innoviva to Participate in the Cantor Global Healthcare Conference
- Sep 19th, 2023 12:30 pm
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
- Sep 18th, 2023 12:00 pm
Innoviva Appoints Stephen Basso as Chief Financial Officer
- Aug 25th, 2023 8:52 pm
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- Aug 2nd, 2023 8:05 pm
Investors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last year
- Jul 23rd, 2023 1:22 pm
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
- Jul 12th, 2023 12:53 am
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
- Jul 11th, 2023 12:00 pm
12 Best Extremely Profitable Stocks to Buy
- Jul 6th, 2023 3:33 pm
Scroll